Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer’s…
Source: prnewswire
Country: United States